143 related articles for article (PubMed ID: 25566684)
21. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
22. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
23. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Pölcher M; Eckhardt M; Coch C; Wolfgarten M; Kübler K; Hartmann G; Kuhn W; Rudlowski C
Cancer Chemother Pharmacol; 2010 May; 66(1):203-7. PubMed ID: 20204367
[TBL] [Abstract][Full Text] [Related]
25. Regulatory considerations on endpoints in ovarian cancer drug development.
Balasubramaniam S; Kim GS; McKee AE; Pazdur R
Cancer; 2017 Jul; 123(14):2604-2608. PubMed ID: 28499075
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
27. Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancer.
Safra T; Andreopoulou E; Levinson B; Borgato L; Pothuri B; Blank S; Tiersten A; Boyd L; Curtin J; Muggia F
Anticancer Res; 2010 Sep; 30(9):3243-7. PubMed ID: 20944093
[TBL] [Abstract][Full Text] [Related]
28. Primary chemotherapy in epithelial ovarian cancer.
Hurwitz HI; McGuire WP
Obstet Gynecol Clin North Am; 1994 Mar; 21(1):141-54. PubMed ID: 7912423
[TBL] [Abstract][Full Text] [Related]
29. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
30. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
31. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
32. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
34. Consolidation/maintenance chemotherapy for ovarian cancer.
Markman M
Curr Oncol Rep; 2003 Nov; 5(6):454-8. PubMed ID: 14521803
[TBL] [Abstract][Full Text] [Related]
35. Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S; Bowering V; Karakasis K; Oza AM
Expert Opin Drug Saf; 2015 Aug; 14(8):1305-16. PubMed ID: 26051946
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial.
Pignata S; Scambia G; Savarese A; Breda E; Sorio R; Pisano C; Lorusso D; Cognetti F; Vernaglia Lombardi A; Gebbia V; Scollo P; Morabito A; Signoriello G; Perrone F
Oncology; 2009; 76(1):49-54. PubMed ID: 19039248
[TBL] [Abstract][Full Text] [Related]
38. [Intraperitoneal chemotherapy in ovarian carcinoma. Life prolonging in selected patients].
Ottevanger PB
Ned Tijdschr Geneeskd; 2009 Mar; 153(11):503-7. PubMed ID: 19402326
[No Abstract] [Full Text] [Related]
39. Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?
Apolone G; Buda A
Ann Oncol; 2004 Sep; 15(9):1443-4; author reply 1444. PubMed ID: 15319253
[No Abstract] [Full Text] [Related]
40. The importance of dose and schedule in cancer chemotherapy: epithelial ovarian cancer.
Mainwaring PN; Gore ME
Anticancer Drugs; 1995 Oct; 6 Suppl 5():29-41. PubMed ID: 8845493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]